CytoSorbents Q4 revenue $9.2mln, FY22 revenue $37mln, expects Q4 gross margin 73%-75%.
ByAinvest
Monday, Jan 12, 2026 7:03 am ET1min read
CTSO--
• Q4 revenue expected at $9.2mln, FY25 at $37mln • Gross margins in Q4 expected at 73%-75% • DrugSorb-ATR De Novo Pre-Submission Meeting with FDA scheduled for this month • De Novo Application filing expected this quarter, regulatory decision in mid-2026 • STAR-T study results accepted for publication in a top cardiac surgery journal • Management to host in-person investor meetings during J.P. Morgan Healthcare Conference week
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet